The Parkinson disease therapeutics market is likely to register substantial gains in coming years owing to growing incidences of Parkinson’s disease, growing use of MAO-B inhibitors, and increasing investments in R&D of novel drugs for numerous chronic diseases and weak economies. Parkinson’s disease is referred as a brain disorder that leads to stiffness, shaking, as well as difficulty with walking, coordination, and balance.

It tends to affect the nerve cells in the brain that are known for producing dopamine. The treatments that are available are largely focused on surging the dopamine levels in the patient’s brain, or by controlling the symptoms themselves.

The Parkinson disease therapeutics market is bifurcated in terms of drug class, route of administration, end-use, and regional landscape.

With respect to drug class, the Parkinson diseases therapeutics market is categorized into glutamate antagonist, MAO-B inhibitors, CO*/MT inhibitors, adenosine A2A antagonist, dopamine agonist, levodopa/carbidopa, and others. In 2020, MAO-B inhibitors segment was valued at around $701 million and is projected to increase at a CAGR of more than 4.8% over the estimated time period. This anticipated growth is attributed to treatment of symptoms such as tremor, stiffness etc. associated with Parkinson’s disease.

This type of drug class also offers some benefit for the motor symptoms of Parkinson disease and are highly useful as an add-on to other medicines, including levodopa or early monotherapy. When used with other medicines, MAO-B inhibitors might extend ???on??? time and decrease reduce ???off??? time.

Based on route administration, the market is classified into transdermal, subcutaneous, oral, and others. Among these, oral segment was valued at approximately $3,415 million in 2020 and is likely to grow at a CAGR of about 4.9% over the forecast time period owing to ease of ingestion.

In terms of end-use, the overall Parkinson diseases therapeutics market is divided into pediatric and adult. In 2020, pediatric segment was valued at around $829 million and is expected to expand at a CAGR of more than 4.4% over the forthcoming time period owing to growing incidences of Parkinson’s disease.

With pediatric parkinsonism, a child might have various symptoms of Parkinson’s disease without having the same disorder. Symptoms may include slow movements and falls, tremors, and balance issues.

From a regional frame of reference, Parkinson disease therapeutics market in Middle East & Africa was valued at more than $160 million in 2020 and is projected to expand at a CAGR of around 6.7% over the forecast time period. This anticipated growth is ascribed to the increasing investments in research & development of novel drugs for numerous chronic diseases and weak economies.